Drug Profile
RBx 2258
Alternative Names: Pamirosin; Parvosin; SPM 969Latest Information Update: 13 Sep 2006
Price :
$50
*
At a glance
- Originator Ranbaxy Laboratories
- Class Urologics
- Mechanism of Action Alpha 1 adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Benign prostatic hyperplasia
Most Recent Events
- 06 Nov 2004 Suspended - Phase-I for Benign prostatic hyperplasia in Japan (PO)
- 06 Nov 2004 Suspended - Phase-I for Benign prostatic hyperplasia in USA (PO)
- 06 Nov 2004 Suspended - Phase-II for Benign prostatic hyperplasia in Europe (PO)